18.61
0.65 (3.62%)
| Penutupan Terdahulu | 17.96 |
| Buka | 17.97 |
| Jumlah Dagangan | 544,282 |
| Purata Dagangan (3B) | 1,662,010 |
| Modal Pasaran | 1,418,877,824 |
| Harga / Pendapatan (P/E TTM) | 58.16 |
| Harga / Jualan (P/S) | 8.43 |
| Harga / Buku (P/B) | 5.74 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 19 Mar 2026 |
| Margin Keuntungan | 3.86% |
| Margin Operasi (TTM) | 51.85% |
| EPS Cair (TTM) | 0.120 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 7,882.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 15.21% |
| Nisbah Semasa (MRQ) | 5.61 |
| Aliran Tunai Operasi (OCF TTM) | 34.67 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 40.54 M |
| Pulangan Atas Aset (ROA TTM) | -0.40% |
| Pulangan Atas Ekuiti (ROE TTM) | 2.88% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Monte Rosa Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.25 |
|
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.73% |
| % Dimiliki oleh Institusi | 101.33% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 37.00 (Piper Sandler, 98.82%) | Beli |
| Median | 34.00 (82.70%) | |
| Rendah | 30.00 (Wells Fargo, 61.20%) | Beli |
| Purata | 33.67 (80.92%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 24.89 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Piper Sandler | 14 Jan 2026 | 37.00 (98.82%) | Beli | 24.06 |
| Guggenheim | 08 Jan 2026 | 34.00 (82.70%) | Beli | 25.31 |
| Wells Fargo | 08 Jan 2026 | 30.00 (61.20%) | Beli | 25.31 |
| 16 Dec 2025 | 22.00 (18.22%) | Beli | 18.66 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |